Pro Medicus shares jump as massive US contract win turns heads

Pro Medicus Ltd (ASX: PME) shares are back in favour on Monday after the healthcare imaging software company landed another major US contract.

At the time of writing, the Pro Medicus share price is up 7.19% to $130.89.

Despite today’s gain, it has been a painful stretch for shareholders. Pro Medicus shares are still down around 40% in 2026 and 52% over the past year.

Let’s take a closer look at the release.

A $90 million US contract lands

In its ASX release, Pro Medicus said its US subsidiary, Visage Imaging, has signed a 7-year, $90 million contract with Beth Israel Lahey Health.

Beth Israel Lahey Health is a healthcare system based in Boston. It brings together academic medical centres, teaching hospitals, community and specialty hospitals, more than 4,700 physicians, and 39,000 employees.

The network has 14 hospitals serving patients in Eastern Massachusetts and Southern New Hampshire.

Under the contract, Beth Israel Lahey Health will use Pro Medicus’ cloud-based Visage 7 Enterprise Imaging Platform.

The deal covers Visage 7 Viewer, Visage 7 Workflow, and Visage 7 Open Archive.

The software will be used to view diagnostic images, manage imaging workflow, and store archived images across the health network.

The company said the rollout will begin immediately, with go-live targeted for the first quarter of calendar year 2027.

Why investors are taking notice

The size of the contract is already significant, but the way it is priced appears to be another reason investors are liking the update.

Pro Medicus said the contract is based on a transactional licensing model, which gives the agreement potential upside if usage grows over time.

It also expands the company’s cloud-based footprint in the North American market.

Chief Executive Dr Sam Hupert said:

Beth Israel Lahey Health provides extraordinary, cutting-edge patient care.

They join an ever-growing list of Visage 7 clients to opt for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

He also noted:

Our pipeline remains strong and spans all market segments. This deal is for our ‘full stack’ comprising all three core Visage products, namely viewer, workflow and archive, a trend we see continuing.

A senior executive is leaving

The update also comes as The Australian reported that Clayton Hatch will leave the business on 14 August.

Hatch has spent almost 18 years with the company, including a long period as Chief Financial Officer. He has most recently worked as head of business operations and investor relations.

While his departure isn’t the main focus of today’s share price move, it is still notable given his long history with the company.

The post Pro Medicus shares jump as massive US contract win turns heads appeared first on The Motley Fool Australia.

More reading

• How much could the Pro Medicus share price rise in the next year?
• Pro Medicus inks $90m contract
• 2 beaten-down ASX shares to hold until 2036
• 3 amazing ASX growth shares to buy and hold forever
• ASX tech shares vs. ATEC ETF: How they fared during sector downturn

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.